US Biosimilar Boom Confronts a Policy Reckoning on Drug Pricing

INCHEON, KOREA – July 23, 2026

The American biosimilar market is hitting its stride, demonstrating robust growth and delivering on its long-held promise of competition for high-cost biologic medicines. A new report from Samsung Bioepis paints a picture of a market in rapid expansion, with 96 biosimilars now approved and 71 launched in the United States. Yet, this success story is unfolding against a turbulent policy backdrop, where a battle over the future of the 340B Drug Pricing Program threatens to create significant headwinds and reshape the economic incentives that govern medication access for the nation's most vulnerable patients.

A Market of Contrasts: Rapid Growth and Pricing Paradoxes

Samsung Bioepis's fourteenth edition of its US Biosimilar Market Report, released today, confirms the sector's strong momentum. As of June 2026, the market has seen a surge in competition, particularly in high-spend therapeutic areas. Immunology biosimilars for blockbuster drugs like adalimumab, tocilizumab, and ustekinumab have shown remarkable uptake, with average market penetration increasing by 25% year over year. This growth is a clear indicator that payers and health systems are increasingly embracing these lower-cost alternatives to drive down spending.

"The US drug pricing landscape continues to shift toward greater transparency and accountability," noted Thomas Newcomer, Senior Vice President and Head of US Commercial at Samsung Bioepis, in the company's announcement. His observation underscores the industry's focus on navigating a complex web of pricing and reimbursement dynamics.

The report also highlights nuanced performance differences that reveal the market's complexity. For instance, biosimilars for ustekinumab (referencing Stelara) are gaining market share at a significantly faster pace than those for adalimumab (referencing Humira). This disparity is likely a function of market maturity; the adalimumab space became highly saturated with numerous competitors in 2023, while the ustekinumab market is newer, presenting a fresh opportunity for rapid savings capture. The initial biosimilar entrants into a new market often see the swiftest uptake as systems race to switch from the high-cost originator.

More puzzling, however, are findings of sharp Average Sales Price (ASP) increases for select biosimilars, including a bevacizumab (oncology) and a ranibizumab (ophthalmology) product. While competition typically drives prices down, these anomalies suggest other market forces are at play. Such increases could be attributed to a number of factors, including limited competition for a specific formulation, supply chain disruptions, or strategic pricing adjustments following a change in commercialization partners. These pricing paradoxes demonstrate that the path to system-wide savings is not always a straight line.

The 340B Shadow: Reform Efforts Cloud Market Outlook

The most significant variable shaping the future of biosimilar adoption is the intense debate surrounding the 340B Drug Pricing Program. This federal program allows qualifying hospitals and clinics that serve a high number of low-income patients to purchase outpatient drugs at a steep discount. However, the program's structure has long been a source of tension, and current reform efforts could fundamentally alter the biosimilar landscape.

Historically, research has shown that 340B hospitals have a lower rate of biosimilar utilization compared to their non-340B counterparts. The reason is a matter of simple economics: because the 340B discount is calculated off a drug's list price, the higher-priced originator biologic often generates a larger profit margin for the hospital than its lower-priced biosimilar competitor. This financial incentive can inadvertently slow the adoption of cost-saving biosimilars within the very institutions designed to serve vulnerable populations.

Now, the program itself is in flux. The Health Resources and Services Administration (HRSA) has signaled its intent to shift from the program's traditional upfront discount model to a post-sale rebate system, a move that has sent shockwaves through the provider community. While a federal court vacated an initial pilot program earlier this year on procedural grounds, HRSA is moving forward with a new proposal. “The shift from upfront discounts to post-sale rebates would create a cash-flow crisis for many of our members,” a healthcare association executive noted. “Hospitals would have to pay the full price upfront and wait for reimbursement, straining resources that are essential for patient care.”

Congress is also stepping in with bipartisan legislative proposals, such as the SECURE 340B Act and the 340B for Patients Act, each aiming to bring clarity, transparency, and new rules to the program. This flurry of regulatory and legislative activity creates profound uncertainty for all stakeholders, from drug manufacturers to the safety-net providers who depend on the program's financial benefits to stay afloat.

A Strategic Play for Intelligence

In this environment of high stakes and deep uncertainty, Samsung Bioepis's role extends beyond that of a product developer. By consistently publishing its detailed quarterly market analysis, the company has positioned itself as a critical source of market intelligence. This commitment to data transparency provides a valuable public service, offering policymakers, payers, providers, and investors a granular view of market trends, pricing dynamics, and competitive shifts.

This strategic focus on thought leadership helps stakeholders make more informed decisions in a notoriously opaque market. By illuminating trends like the rapid uptake of immunology biosimilars and the complex pricing behaviors of specific products, the reports help build a common understanding of the challenges and opportunities at hand. For a company navigating the highly competitive biosimilar space, establishing a reputation for reliable, data-driven insight is a powerful differentiator.

The Patient Equation: Translating Savings into Access

Ultimately, the complex interplay between market competition and policy reform must be measured by its impact on patients. The core promise of biosimilars is not just system-level savings, but tangible benefits for individuals in the form of lower out-of-pocket costs and broader access to life-changing therapies. However, the market distortions highlighted in the report and amplified by the 340B debate threaten to undermine that promise.

“Our primary concern is that these market complexities and misaligned incentives mean potential savings aren't translating into lower out-of-pocket costs for patients,” commented a senior leader at a national patient advocacy group. When a hospital's financial incentives favor a higher-cost originator, the savings from biosimilar competition may not be fully realized by the health system or passed on to commercially insured patients through lower premiums and cost-sharing.

As policymakers in Washington D.C. weigh the future of the 340B program and other drug pricing reforms, including those in the Inflation Reduction Act, they face the challenge of aligning incentives across the entire healthcare ecosystem. Ensuring that the powerful forces of market competition truly benefit the end consumer will require careful and deliberate policy design that prioritizes patient affordability and sustainable access.